Our Business

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. The company is partnered with Auxilium Pharmaceuticals, Inc. for injectable collagenase (XIAFLEX®). XIAFLEX is approved in the U.S. for the treatment of Dupuytren’s contracture in adults with a palpable cord in the palm. Auxilium is also developing XIAFLEX for the treatment of Peyronie's disease, which is currently in Phase III pivotal clinical trials, as well as for Frozen Shoulder (Adhesive Capsulitis) and cellulite, which are in Phase IIa and Ib clinical trials, respectively.

Pfizer, Inc. is responsible for marketing injectable collagenase (trademarked XIAPEX® in Europe) for Dupuytren’s contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie’s disease in these same territories.

Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren’s contracture and Peyronie’s disease in Japan and Actelion Pharmaceuticals Ltd. has the development and commercialization rights for these two indications in Canada, Australia, Brazil and Mexico.

BioSpecifics is developing XIAFLEX internally for human and canine lipomas. In the second quarter of 2012, BioSpecifics expects to initiate a Phase II dose escalation clinical trial in humans and a placebo controlled opt-in trial for canines.